Oddway International Announces Addition Of Tasigna In Their Product Inventory

"Tasigna 150mg Capsules Composition of Nilotinib by Novartis Pharma Stein AG"
DARIYAGANJ, India - July 19, 2017 - PRLog -- Oddway International, leading distributor, exporter and wholesaler of generic and brand pharmaceuticals introduces yet another efficient medication; Tasigna manufactured by Novartis Pharma Stein AG contains Nilotinib in a pack of 28 Capsules, in their wide spread of product directory.

Tasigna (Nilotinib) is a cancer medication that interferes with the growth and spread of cancer cells in the body. Tasigna 150 mg is used to treat a type of blood cancer called Philadelphia chromosome positive chronic myeloid leukemia (CML).

Oddway International notifies of more than thirty categories of product catalogues with hundreds of quality products in each category offered at a reasonable price. They take credit in 'quality control' and 'quality assurance' to offer their local and international buyers improve health and wellness with their quality medicine.

About Oddway International

Oddway International is an international wholesale distributor of pharmaceutical and medical products serving to Retail Chains, Independent Retail Pharmacies, Wholesale Distributors and Institutional Providers such as Hospitals, Health Systems and Long-Term Care Providers. They constantly strive to provide safe and cost effective healthcare to improve the standard of living throughout the world. Their aim throughout is customer satisfaction, achieved through their core values of Quality, Affordability, Customer Care, Choice, Accessibility, Partnership, Responsibility.

For more information visit: http://www.oddwayinternational.com

Media Contact
Oddway International
Posted By:***@oddwayinternational.com Email Verified
Tags:Tasigna 150mg Capsules, Nilotinib Capsules Price
Location:Dariyaganj - Delhi - India
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Oddway International News
Most Viewed
Daily News

Like PRLog?
Click to Share